Cantor Fitzgerald Raises Earnings Estimates for Septerna

Septerna, Inc. (NASDAQ:SEPN) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for Septerna in a report issued on Tuesday, November 11th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($1.07) for the year, up from their prior forecast of ($1.90). Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. Cantor Fitzgerald also issued estimates for Septerna’s FY2026 earnings at ($1.27) EPS.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.28). The business had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%.

Several other equities research analysts also recently issued reports on SEPN. HC Wainwright upped their price target on Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Septerna from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.75.

Septerna Stock Down 0.1%

Shares of Septerna stock opened at $19.23 on Thursday. Septerna has a 52 week low of $4.17 and a 52 week high of $28.99. The business has a 50 day moving average price of $19.07 and a 200-day moving average price of $13.61. The company has a market cap of $857.37 million and a PE ratio of -12.74.

Institutional Trading of Septerna

Hedge funds have recently added to or reduced their stakes in the stock. Covestor Ltd boosted its stake in Septerna by 55.8% in the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after acquiring an additional 1,296 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after purchasing an additional 1,315 shares during the period. Rhumbline Advisers lifted its stake in Septerna by 16.6% in the first quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after purchasing an additional 3,323 shares during the last quarter. Deutsche Bank AG grew its holdings in Septerna by 53.3% during the first quarter. Deutsche Bank AG now owns 15,968 shares of the company’s stock valued at $92,000 after purchasing an additional 5,549 shares during the period. Finally, Rangeley Capital LLC grew its holdings in Septerna by 10.7% during the second quarter. Rangeley Capital LLC now owns 58,605 shares of the company’s stock valued at $619,000 after purchasing an additional 5,655 shares during the period.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.